Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI). (2020) Rogiers A, Tondini C, Grimes JM, Trager MH, Nahm S, Zubiri L, Papneja N, et al. Conference contribution A TNM-Immune (TNM-I) classification staging system for predicting survival in colon cancer in a multicenter international SITC study (2020) Mlecnik B, Bifulco C, Marliot F, Lugli A, Nagtegaal I, Hartmann A, Van Den Eynde M, et al. Conference contribution Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3) (2020) Fasching P, Neven P, Jerusalem G, Beck JT, Chan A, De Laurentiis M, Bianchi GV, et al. Conference contribution Quality-adjusted survival with ribociclib plus fulvestrant (R plus F) versus placebo plus fulvestrant (P plus F) in postmenopausal women (PMW) HR+/HER2-advanced breast cancer (ABC) based on the MONALEESA-3 trial (2020) Jerusalem G, Delea T, Martin Jimenez M, De Laurentiis M, Nusch A, Beck JT, Chan A, et al. Conference contribution Immunoscore predicts significant differences in time to recurrence in stage I colon cancer patients (2019) Galon J, Hermitte F, Mlecnik B, Marliot F, Bifulco C, Lugli A, Nagtegaal I, et al. Conference contribution Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma (2019) Van Herpen CM, Agarwala SS, Hauschild A, Berking C, Thaddeus Beck J, Schadendorf D, Jansen R, et al. Journal article MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies (2018) Galon J, Mlecnik B, Hermitte F, Marliot F, Bifulco C, Lugli A, Nagtegaal ID, et al. Conference contribution Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) (2018) Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, et al. Conference contribution International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study (2018) Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, et al. Journal article Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab (2016) Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, et al. Journal article